Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy
Condition(s):Inflammatory MyopathyLast Updated:August 28, 2019Unknown status
Hide Studies Not Open or Pending
Condition(s):Inflammatory MyopathyLast Updated:August 28, 2019Unknown status
Condition(s):Polymyalgia RheumaticaLast Updated:September 4, 2019Unknown status
Condition(s):Inflammatory MyopathyLast Updated:January 23, 2020Unknown status
Condition(s):Chronic Spontaneous UrticariaLast Updated:May 20, 2021Unknown status
Condition(s):Renal Cell Cancer Metastatic; Kidney Cancer MetastaticLast Updated:February 8, 2018Terminated
Condition(s):Melanoma MetastaticLast Updated:April 5, 2018Terminated
Condition(s):B-Cell Leukemia; B-Cell LymphomaLast Updated:March 18, 2024Withdrawn
Condition(s):DermatomyositisLast Updated:December 5, 2022Enrolling by invitation
Condition(s):Chronic Versus Graft Host DiseaseLast Updated:June 23, 2020Completed
Condition(s):Autoimmune Hemolytic AnemiaLast Updated:February 18, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.